Jun Suk Kim
Impact in
- Hepatology top 0.1%
- Hepatocellular Carcinoma Treatment and Prognosis
- Liver physiology and pathology
- Cancer Research top 1%
- Cancer, Hypoxia, and Metabolism
Papers in
-
- Advanced MIMO Systems Optimization 15
- Millimeter-Wave Propagation and Modeling 9
- IoT Networks and Protocols 6
- Oncology 28
- Pancreatic and Hepatic Oncology Research 6
- Co-authors
- Yoon‐Koo Kang (3 shared papers)Zhendong Chen (2 shared papers)Zhongzhen Guan (2 shared papers)Chao-Jung Tsao (2 shared papers)Hongming Pan (2 shared papers)Tsai‐Sheng Yang (2 shared papers)Ann‐Lii Cheng (2 shared papers)Jianming Xu (2 shared papers)
- Journals
- Cancer Research and Treatment (9 papers)Cancer Chemotherapy and Pharmacology (8 papers)Blood (5 papers)ACS Nano (5 papers)Investigational New Drugs (4 papers)
- Partner nations
- South KoreaUnited StatesJapan
In The Last Decade
Jun Suk Kim
136 papers receiving 7.9k citations
Jun Suk Kim's Hit Papers
Peers
Comparison fields: 5 of 153
- Hepatology 3.3k
- Cancer Research 924
- Pathology and Forensic Medicine 971
- Oncology 1.5k
- Epidemiology 931
Countries citing papers authored by Jun Suk Kim
This map shows the geographic impact of Jun Suk Kim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jun Suk Kim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jun Suk Kim more than expected).
Fields of papers citing papers by Jun Suk Kim
This network shows the impact of papers produced by Jun Suk Kim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jun Suk Kim. The network helps show where Jun Suk Kim may publish in the future.
Co-authors
The 25 scholars most cited alongside Jun Suk Kim, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 137 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial Hit paper breakdown → | 2008 | 4666 |
| 2 | Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study Hit paper breakdown → | 2011 | 351 |
| 3 | 2012 | 223 | |
| 4 | 2018 | 211 | |
| 5 | 2004 | 158 | |
| 6 | 2012 | 110 | |
| 7 | 2016 | 97 | |
| 8 | 2011 | 96 | |
| 9 | 2011 | 71 | |
| 10 | 2005 | 64 | |
| 11 | 2005 | 61 | |
| 12 | 2019 | 59 | |
| 13 | 2017 | 58 | |
| 14 | 2011 | 54 | |
| 15 | 2011 | 51 | |
| 16 | 2004 | 46 | |
| 17 | 2017 | 46 | |
| 18 | 2012 | 46 | |
| 19 | 2014 | 43 | |
| 20 | 2008 | 38 |
About Jun Suk Kim
Jun Suk Kim is a scholar working on Electrical and Electronic Engineering, Oncology, Molecular Biology, Materials Chemistry and Computer Networks and Communications, having authored 137 papers that have together received 8.1k indexed citations. Recurring topics across this work include Advanced MIMO Systems Optimization (15 papers), Graphene research and applications (11 papers), Carbon Nanotubes in Composites (10 papers), Millimeter-Wave Propagation and Modeling (9 papers), IoT Networks and Protocols (6 papers), Cooperative Communication and Network Coding (6 papers), Pancreatic and Hepatic Oncology Research (6 papers) and TGF-β signaling in diseases (5 papers). The work is most often cited by research in Hepatology (3.3k citations), Cancer Research (924 citations), Pathology and Forensic Medicine (971 citations), Oncology (1.5k citations) and Epidemiology (931 citations). Jun Suk Kim has collaborated with scholars based in South Korea, United States and Japan. Frequent co-authors include Yoon‐Koo Kang, Zhendong Chen, Zhongzhen Guan, Chao-Jung Tsao, Hongming Pan, Tsai‐Sheng Yang, Ann‐Lii Cheng, Jianming Xu, D. Voliotis and Shukui Qin. Their work appears in journals such as Cancer Research and Treatment, Cancer Chemotherapy and Pharmacology, Blood, ACS Nano and Investigational New Drugs.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.